Stockwatch: The impossible takes a little too long
This article was originally published in Scrip
When Tony Blair joined Bill Clinton by satellite link to the White House in 2000 to announce the sequencing of the human genome, biotech stocks soared with the implication that genomics would result in a cure for any disease. Even today, nearly twelve years, recently approved targeted therapies for blood and skin cancers imply that the application of genomic data and molecular biology can result in a treatment for most unmet clinical needs, eventually.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.